跳至主要内容
临床试验/NCT05750498
NCT05750498招募中不适用

Autoimmune Liver Disease Network for Kids (A-LiNK): Using Patient Data to Transform Care and Improve Outcomes for Children, Adolescents, and Young Adults With Autoimmune Liver Disease

Children's Hospital Medical Center, Cincinnati16 个研究点 分布在 1 个国家目标入组 800 人开始时间: 2022年4月28日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
招募中
入组人数
800
试验地点
16
主要终点
Baseline disease characteristics in the population

研究概览

简要总结

The Autoimmune Liver disease Network for Kids (A-LiNK) is a multi-institutional group with the mission to deliver the best care to kids with pediatric autoimmune liver disease (AILD).

This study will establish a shared clinical registry and a learning health network for the participating sites focusing on collecting and transmitting clinical measurement data, information about processes, and participation in an improvement collaborative.

Pediatric Autoimmune Hepatitis (AIH) and Primary Sclerosing Cholangitis (PSC), represent a spectrum of AILD which present unique diagnostic and therapeutic challenges.A lack of accepted guidelines for disease monitoring or symptom management results in wide treatment variation with liver transplants indicated in refractory, progressive disease.

The aims of A-LiNK are to:

1.) Create a learning health network focused on patient-centered outcomes research characterized by transparent sharing among centers, common priorities, and feasible plans for implementing new practices; 2) shift from traditional investigator-driven study to a patient and family-centered approach, and 3.) improve clinical outcomes and quality of life for pediatric AILD patients.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

性别
All
接受健康志愿者
否

入选标准

  • •Clinical diagnosis of autoimmune hepatitis (AIH)
  • •Clinical diagnosis of primary sclerosing cholangitis (PSC)
  • •Clinical diagnosis of autoimmune sclerosing cholangitis (ASC)

排除标准

  • •History of liver transplant

研究组 & 干预措施

Children and adolescents with Autoimmune Liver Disease

Pediatric patients with a diagnosis of autoimmune hepatitis, or primary sclerosing cholangitis.

干预措施: No interventions (Other)

结局指标

主要结局

Baseline disease characteristics in the population

时间窗: 2034

Disease relapse and biochemical remission rates

时间窗: 2034

Biochemical remission = transaminases (ALT/AST) within the upper limit of normal for age

Complications of disease

时间窗: 2034

Including ascites, esophageal variceal bleeding, cholangitis, hepatic encephalopathy, listed for liver transplant, hepatocellular carcinoma, or cholangiocarcinoma

Side-effects of steroids

时间窗: 2034

Including hypertension, diabetes mellitus, low bone mineral density, glaucoma, cataract, overweight, obesity

Pediatric Quality of Life Inventory (PedsQL 4.0) Generic Core Scales Short Form 15

时间窗: 2034

Health-related quality of life

Racial and ethnic disparities

时间窗: 2034

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (16)

Loading locations...

相似试验